A Study to Evaluate ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With Zilebesiran
Recruiting · NCT07553442 · Interventional (participants receive a specific treatment) · Lead sponsor: Alnylam Pharmaceuticals
View the official record on ClinicalTrials.gov →Interventions studied
ALN-AGT01 RVRPlaceboZilebesiran
What this trial is about
The purpose of this study is to evaluate the efficacy, pharmacodynamics (PD), and safety of ALN-AGT01 RVR in participants with mild to moderate hypertension pretreated with zilebesiran.
Who can take part
Age range
18 Years to 75 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 2
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Is an adult participant with a mean seated office systolic blood pressure (SBP) of at least 130 mmHg and no more than than 170 mmHg
- Either not taking antihypertensive medication or on stable therapy with up to 2 antihypertensive medications
- Part B: Inclusion Criteria
- Is an adult participant with a mean seated office SBP of at least 140 mmHg and no more than 170 mmHg
- Has discontinued all prior antihypertensive medication other than a calcium channel blocker (CCB) and/or thiazide/thiazide-like diuretic (if taking) for at least 3 weeks
- Both Parts:
Exclusion criteria
- Has known secondary hypertension or serum potassium more than 5 mmol/L
- Has an estimated glomerular filtration rate (eGFR) less than 30 mL/min/1.73m\^2
- Note: other protocol defined inclusion / exclusion criteria apply
Where it is running
3 locations listed across 3 US states.
- Clinical Trial Site - Lake Forest, California, United States
- Clinical Trial Site - Tampa, Florida, United States
- Clinical Trial Site - Savannah, Georgia, United States